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aerosolized salbutamol in horses: five cases
Daniela Casoni*†, Claudia Spadavecchia and Chiara Adami†Abstract
Prevention and treatment of intraoperative hypoxemia in horses is difficult and both efficacy and safety of
therapeutic maneuvers have to be taken into account. Inhaled salbutamol has been suggested as treatment of
hypoxia in horses during general anesthesia, due to safety and ease of the technique. The present report describes
the occurrence of clinically relevant unwanted cardiovascular effects (i.e. tachycardia and blood pressure
modifications) in 5 horses undergoing general anesthesia in dorsal recumbency after salbutamol inhalation.
Balanced anesthesia based on inhalation of isoflurane in oxygen or oxygen and air and continuous rate infusion
(CRI) of lidocaine, romifidine, or combination of lidocaine and guaifenesine and ketamine was provided. Supportive
measures were necessary to restore normal cardiovascular function in all horses but no long-term adverse effects
were noticed in any of the cases.
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Despite delivery of high-inspired oxygen concentration,
suboptimal arterial partial pressure of oxygen (PaO2)
and hypoxemia are frequently observed in horses under-
going general anesthesia [1–4]. In this context, hypox-
emia, defined as a PaO2 lower than 60 mm Hg is
secondary to considerable changes in ventilation and
blood flow distribution in the equine lung, among which
the most important is the development of a large intra-
pulmonary right-to-left vascular shunting [3,5]. Dorsal
recumbency is positively correlated with the incidence of
hypoxaemia. Preventing or treating intraoperative hyp-
oxaemia has proved difficult and no ideal technique is
currently available in the clinical practice. In light of its
supposed efficacy in improving gas exchange efficiency,
clenbuterol, a β-adrenergic agonist, was administered
intravenously with inconsistent [6,7] effects. However,
the administration of salbutamol aerosol in intubated
horses with low PaO2 has been previously demonstrated ef-
fective [1]. Salbutamol is a non-catecholamine β-adrenergic
agonist with prevalent selectivity for β2 receptors, used in
human patients affected by asthma and in horses with* Correspondence: daniela.casoni@vetsuisse.unibe.ch
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unless otherwise stated.recurrent airways diseases. Although it is well known that
there is a large inter individual variation in response to
β-adrenoreceptor ligands in vivo, the β2–selectivity
in vitro is characterized by a higher intrinsic activity
and higher affinity at β2 than at β1-adrenoreptors [8].
The mechanism of its beneficial action on improving
PaO2 under anesthesia is still unclear. It has been sug-
gested that the improvement of ventilation/perfusion
(V/Q) mismatches is mediated by the opening of small
airways in perfused lung regions, thereby allowing up-
take of oxygen by blood in those areas [1]. Improvement
of peripheral airflow obstruction has also been postu-
lated in patients affected by primary pulmonary hyperten-
sion [9]; instead, no improvement of pulmonary oxygenation
secondary to bronchodilator effect has been reported in clin-
ically healthy horses [10]. The technique has the main ad-
vantage of being easy to learn, straightforward, non-invasive
and safe. In case of systemic absorption, salbutamol effects
on β1 and β2 receptors located extrabronchially, could lead
to positive inotropy and chronotropy secondary to cardiac
stimulation and peripheral muscular vasodilation. However,
no tachycardia was observed in horses following salbutamol
administration in clinical settings [1]. In experimental
healthy horses in dorsal recumbency, a positive chron-
otropic effect without clinical relevance was temporarily
recorded [11]. This case series reports the occurrence ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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4 cases, and ventricular arrhythmia associated with sys-
temic arterial hypotension in 1 case following the inhal-
ation of salbutamol aerosol in anaesthetized horses in
dorsal recumbency.
Case presentations
Anesthesia protocol and monitoring
Details relative to the anesthesia protocols for each pa-
tient are summarized in Table 1. After endotracheal in-
tubation, inhalational anesthesia was maintained with
isoflurane in oxygen or in oxygen and air (Table 1)
through a circle system designed for large animal and
connected to an adjustable time cycled ventilator (DHV
1000 Large Animal Ventilator, Surgivet®, Smiths Med-
ical). A multi-parameter-anaesthetic monitor (Datex
Ohmeda S/5, GE) was used in all the cases to continu-
ously monitor invasive and non-invasive arterial blood
pressure, base-apex lead electrocardiogram, partial satur-
ation of oxygen (SpO2), end-tidal CO2 (EtCO2), inhaled
and exhaled oxygen and isoflurane concentrations and
for cases 4 and 5 spirometry pressure-volume loops. Ar-
terial blood was sampled with a closed technique and
the blood gas analysis was performed with Radiometer
ABL 800 Flex, Radiometer Medical A/S, Denmark. Gas
pressures were measured in mmHg and converted to
kPa. Infusion of balanced crystalloid solution (Ringer
Lactate) was provided all over the anesthetic at 10–
20 ml kg−1 h−1. Dobutamine was infused at variable dose
(Table 1) targeting a mean invasive arterial pressure
(MAP) of 70 mmHg.
Salbutamol administration
Salbutamol aerosol (Ventolin® nebulizer, 200 inhalations,
Glaxo Smith Kline, Switzerland) as a racemic mixture
was administered in all the cases for a total maximal
dose of 2 μg kg−1. Salbutamol was sprayed through the
same designed adapter into the Y-piece of the circle sys-
tem (Figure 1) at the beginning of inspiratory phase for
a number of respiratory acts equal to the number of
nebulizations to be sprayed. Number of puffs to be ad-
ministered was calculated for the weight of each patient.
According to the manufacturer, each depression of the
canister nozzle delivers 100 μg of active drug.
Case 1
Twenty-five minutes after the beginning of inhalatory
anesthesia, as arterial blood gas analysis revealed a PaO2 of
9.41 kPa (70.6 mmHg) (FiO2 = 0.92) salbutamol was admin-
istered. Mild hypercapnia (PaCO2 6.97 kPa = 52.3 mmHg)
and lactate concentration of 2.18 mmol/L were detected at
the same time. Ten minutes following the administration,
HR increased from 35 bpm to 48 bpm and remained ele-
vated over 5 minutes. Concomitantly, profuse sweating anda decrease in systolic blood pressure without modification
of the mean arterial pressure (MAP) (78 mmHg) were re-
corded. Heart rate (HR) returned to 34 bpm and concomi-
tantly blood pressure increased as well and remained stable
until the end of anesthesia. PaO2 increased after salbutamol
administration and fifteen minutes later was 13 kPa
(97 mmHg); PaCO2 was 7.33 kPa (55 mmHg) and lac-
tate 2.3 mmol/L. Blood gas analysis was repeated 45 minutes
after salbutamol inhalation and PaO2 decreased again to
79 mmHg. Since the PaCO2 increased concomitantly (8.08
kPa), mechanical ventilation was adapted. The horse recov-
ered assisted uneventfully.
Case 2
Thirty minutes after the beginning of inhalatory anesthesia,
as arterial blood gas analysis revealed a PaO2 of 12.8 kPa
(96 mmHg) (FiO2 = 0.72), salbutamol was administered.
Normocapnia (PaCO2 5.33 kPa = 40 mmHg) and lactate
concentration of 3.08 mmol/L were detected at the same
time. Ten minutes following the administration, HR in-
creased from 46 bpm to 57 bpm and progressively reached
the peak of 72 bpm (15 minutes later) to decrease over the
following 10 minutes to 57 bpm and stabilize around
48 bpm subsequently. During the tachycardia phase, blood
pressure did not change and remained low (MAP around
50 mmHg). Normal MAP could not be restored until HR
decreased to the baseline, despite increasing of the dobuta-
mine dose rate (up to a maximum of 1.5 μg kg−1 min−1)
and the dose rate of fluid infusion. Concomitantly, profuse
sweating was noticed. Fifteen minutes after salbutamol ad-
ministration PaO2 increased to 26.67 kPa (200 mmHg);
PaCO2 was 5.33 kPa (40 mmHg) and lactate 2.28 mmol/L.
Blood gas analysis was repeated 60 minutes after salbuta-
mol administration; PaO2 was 26.13 (196 mmHg) and
PaCO2 was unmodified. The horse recovered assisted
uneventfully.
Case 3
Twenty minutes after the beginning of inhalatory anesthesia,
the arterial blood gas analysis revealed a PaO2 of 14.26 kPa
(107 mmHg) (FiO2 = 0.6). Ten minutes later salbutamol was
administered. Moderate hypercapnia (PaCO2 8.99 kPa =
67.4 mmHg) and lactate concentration of 1.9 mmol/L were
detected at the same time. Five minutes following the ad-
ministration, HR progressively increased from 40 bpm to
57 bpm over 15 minutes and then decrease over the next
10 minutes to baseline. A further mild decrease to a final
HR of 38 bpm was recorded towards the end of anesthesia.
During the tachycardia phase, blood pressure increased
abruptly; the MAP passed from 63 to 105 mmHg, with a
peak of diastolic blood pressure of 90 mmHg, followed by a
progressive slow decrease to normal values. Concomitantly,
the administration of dobutamine was interrupted. A
new blood gas analysis conducted 20 minutes after the
Table 1 Details of anaesthetic protocol for each patient
Case
details
Patient Procedure Premedication Induction Maintenance Ventilation Time of
salbutamol
inhalation
Et Isoflurane% Dobutamine
dose μg kg-1 min−1
Case 1¥ 14 year old,
gelding Swiss
Warm Blood
760 kg
Emergency
explorative
laparotomy
Romifidine1
40 μg kg−1 IV
Ketamine3
2.2 mg kg−1 IV
Isoflurane in oxygen IPPV fr = 8–10 min−1 TV = 10 ml kg−1
I:E ratio: 1:2 Peak PAW = 30 cmH20
PEEP = 5 cmH2O
T0 = 45 Et Iso 1.1% Minimum0.22
Butorphanol2
50 μg kg−1 IV
Diazepam4
100 mcg kg−1 IV
Lidocaine 2% (30 μg kg−1 min−1)
CRI
T1 = 35 Maximum 0.5
At salbutamol
inhalation 0.5
Case 2¥ 12 year old,
mare Island
horse 350 kg
Emergency
explorative
laparotomy
Romifidine1
50 μg Kg−1 IV
Ketamine3
2.2 mg Kg−1 IV
Isoflurane in oxygen and air IPPV fr = 5 min−1 TV = 11.5 ml kg−1
I:E ratio: 1:2 Peak PAW =20 cmH20
T0 = 55 Et Iso 1% Minimum 0.5
Butorphanol2
50 μg kg−1 IV
Diazepam4
50 mcg kg−1 IV
Lidocaine 2% (25 μg kg−1 min−1),
ketamine3 (10 μg kg−1 min−1) and
guafenesin5 (0.4 mg−1 kg−1 min−1) CRI
T1 = 40 Maximum 1.5
At salbutamol
inhalation 0.75Guaifenesine to
effect IV
Case 3* 6 month old,
male Swiss
warm blood
265 kg
Elective scrotal
herniorraphy
and castration
Acepromazine6
30 μg Kg−1 IM
Ketamine3
2.2 mg Kg−1 IV
Isoflurane in oxygen Spontaneous breathing IPPV (after
salbutamol administration) fr = 6 min−1
TV = 15 ml kg−1 I:E ratio: 1:2 Peak
PAW =25 cmH20
T1 = 45 Et Iso 1.1% Minimum 0.6
Romifidine1
50 μg Kg−1 IV
Diazepam4
100 mcg kg−1 IV
Romifidine (0.6 μg kg−1 min−1) CRI T0 = 55 Maximum 1.6
L- Methadone7
50 μg Kg−1 IV
Guaifenesine
to effect IV
At salbutamol
inhalation 0.6
Case 4* 4 month old,
male Polo
Pony 200 kg
Elective
humbelical
herniorraphy
Acepromazine
30 μg kg−1 IM
Ketamine3
2.2 mg kg−1IV
Isoflurane in oxygen and air Spontaneous breathing; IPPV (before
salbutamol administration) TV = 2200 ml
fr = 7 min−1 TV = 13 ml kg−1 (2550 ml)
I:E ratio: 1:2 Peak PAW =30 cmH20
T0 = 35 Et Iso 1.3% Minimum 0.8
Romifidine1
60 μg kg−1
Diazepam4
100 mcg kg−1 IV
T1 = 28 Maximum 1.6
Butorphanol2
40 μg kg−1
At salbutamol
inhalation 1.6
Case 5† 10 year old,
gelding male
Swiss warm
blood 670 kg
Emergency
carpus
arthroscopy
Romifidine1
60 μg kg−1 IV
Ketamine3
2.2 mg Kg−1 IV
Isoflurane in oxygen and air Spontaneous breathing TV =5600 ml T0 = 85 Et Iso 1.1% Minimum 0.12
L- Methadone7
50 μg kg−1 IV
Diazepam4
100 mcg kg−1 IV
Romifidine (0.6 μg kg−1 min−1) CRI T1 = 70 Maximum 0.5
At salbutamol
inhalation 0.12
*This patient was ventilated after hypoxia and hypercapnia were detected; ¥ these patients underwent mechanical ventilation from the beginning of inhalational anesthesia;† this patient was allowed to breath
spontaneously during anesthesia; 1Romifidine, Sedivet ®, 10 mg/ml, Boehringer Ingelheim, Switzerland; 2Butorphanol, Morphasol ®10 mg/ml Graeub AGE, Switzerland; 3Ketamine, Narketan ®, 100 mg/ml, Vetoquinol
Suisse; 4Diazepam, Valium® 5 mg/ml, Roche, Basel, Switzerland; 5Guaifenesine 12.5% solution (currently out of the market); 6Acetilpromazine, Prequillan ®10 mg/ml Arovet AG; 7 L-methadone/fenpipramide 50/2.5 μg kg−1 IV
Polamivet ®, Intervet, Switzerland.
T0 = Time between romifidine injection at the sedation and salbutamol inhalation. T1 = Time between ketamine injection at the injection and salbutamol inhalation expressed in minutes.
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Figure 1 Inhalation of salbutamol. Salbutamol spray canister inserted into the adapter of the Y connection of the circle system during
general anesthesia.
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PaO2 (14.26 kPa = 107 mmHg) and moderate hyper-
capnia was confirmed, therefore mechanical ventilation
was started. The horse recovered assisted uneventfully.
Case 4
Fifteen minutes after the beginning of inhalatory anesthesia,
as arterial blood gas analysis revealed a PaCO2 of 10.04 kPa
(75.3 mmHg) and a PaO2 of 9.34 kPa (70.5 mmHg)
(FiO2 = 0.58), salbutamol was administered. A lactate
concentration of 2.1 mmol/L was detected at the same
time. Concomitantly IPPV was started. Measured tidal
volume was 3.2 L. Spirometric volume- pressure loops
indicated reduced compliance. Ten minutes after sal-
butamol administration, HR progressively increased
from 42 bpm to 69 bpm and 15 minutes later reached
the peak of 72 bpm to progressively decrease over the
following 30 minutes to 57 bpm. A moderate decrease
in the blood pressure was noticed after salbutamol ad-
ministration and dobutamine was continuously admin-
istered over the entire procedure to maintain the MAP
in the range of 69 to 72 mmHg. A new blood gas ana-
lysis conducted 30 minutes after salbutamol administra-
tion and beginning of IPPV revealed a clear improvement
of PaO2 (37.9kPa = 284 mmHg); PaCO2 = 7.28 kPa
and lactate 2.1 mmol/L. The horse recovered assisted
uneventfully.
Case 5
Fifteen minutes after the beginning of inhalatory anesthesia,
arterial blood gas analysis revealed a PaCO2 of 7.04 kPa
(52.8 mmHg) and a PaO2 of 13.65 kPa (102.4 mmHg)(FiO2 = 0.65). A second blood gas analysis was conducted
45 minutes later and revealed a PaCO2 of 7.49 kPa
(56.2 mmHg) and a PaO2 of 10.18 kPa (76.4 mmHg)
(FiO2 = 0.87). At this time point, salbutamol was ad-
ministered. Five minutes after salbutamol administra-
tion, a profuse sweating started and HR progressively
increased from 30 bpm to 46 bpm and in the following
15 minutes increased abruptly to 80 bpm and over ten
further minutes reached the peak of 100 bpm. A run of
premature ventricular complexes appeared on the
sinus rhythm, followed by some regular sinus com-
plexes, and immediately after ventricular tachycardia suc-
ceeded (recorded HR was between 95 and 100 bpm).
Parallel with the development of tachycardia, the mean
blood pressure decreased sharply from 80 to a minimum
of 45 mmHg (Figure 2). Dobutamine CRI was stopped
and a bolus of colloids of 2 ml kg−1 h−1 (Voluven® 6% bal-
anced, Fresenius Kabi, CH) was administered over 10 mi-
nutes. A bolus of 1.5 mg kg−1lidocaine was administered
over 5 minutes. Continuous rate infusion of phenylephrine
was started at 0.01 μg kg−1 min−1 and then stopped when
the MAP reached a value above 60 mmHg. Consequently,
the HR decreased slowly and progressively and synusal
rhythm reappeared. A new blood gas analysis conducted
20 minutes after salbutamol administration at FiO2 of 0.8
revealed ameliorated PaO2 (21.2 kPa = 159 mmHg) and
moderate hypercapnia (PaCO2 = 8.44 kPa = 63.3 mmHg).
Lactate plasma level (1.0 mmol/L) did not increase. After
the end of the surgical procedure, which terminated 50 mi-
nutes after salbutamol administration, the horse was
transferred to the recovery stall under ECG monitoring.
Blood gas analysis at the end of the surgery was unvaried:
Figure 2 Cardiovascular effect of salbutamol inhalation. HR = heart rate (along the left y axis) and IBP = invasive blood pressure (along the
right y axis) variations after salbutamol inhalation. On the x axis time 0 represents salbutamol inhalation. Systolic, mean and diastolic blood
pressures are represented.
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and lactate plasma level 1.1 mmol/L. The trend of pro-
gressive, slow decrease of HR was confirmed and when
the horse showed the first sign of nystagmus, romifidine
at 10 μg kg−1 was administered as post-operative sedation
and the ECG monitoring interrupted. The horse recovered
assisted uneventfully.
Conclusions
This case series describes the occurrence of adverse car-
diovascular effects in 5 horses associated with the inhal-
ation of salbutamol at clinical advised doses during
general anesthesia. The treatment of suboptimal oxygen
arterial pressure in horses has proven to be difficult and
no efficacious therapy to counteract it has been estab-
lished yet. The authors utilize in their daily practice in-
halational salbutamol as treatment of hypoxemia taking
advantage of the ease and the non-invasiveness of the
technique. However, the occurrence of a cardiovascular
impairment in the five cases described above warns
against potential detrimental effects of the β-2 agonist
inhalation. To the best of the authors’ knowledge there
are no previous reports in literature describing the ap-
pearance of cardiovascular adverse effects after salbuta-
mol administration in a clinical setting. In 4 out of 5horses, the cardiovascular impairment could be cor-
rected by adjusting the supportive therapy already ad-
ministered during the anesthesia. However, in one horse
(case 5) the occurrence of ventricular tachycardia and
the severe decreasing of the blood pressure required
additional therapy. As the peripheral vasodilation was a
major concern and as the surgical operation was almost
completed, the hypotension was treated with phenyleph-
rine in light of its prevalent action as vasoconstrictor
acting on post-synaptic α-1 receptors. In none of the
cases was cardiac output measured before or after the
salbutamol administration, therefore variations in blood
pressure and heart rhythm were the only objective indi-
cators of cardiovascular derangement. In light of the
strong temporal association between the administration
of salbutamol and the recorded cardiovascular impair-
ment, the authors consider the inhalation of salbutamol
its most likely cause. In none of the cases, was the sud-
den tachycardia either associated with surgical incision
or further painful stimulation and supportive measures
to restore the cardiovascular stability were successful.
Hypovolemia was unlikely the case of the cardiovascular
modification in case 1 as the observed tachycardia was
of short duration and associated with sweating. In case
2, despite the suboptimal blood pressure recorded at the
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fluid deficit, hypovolemia cannot explain the sudden
tachycardia and the profuse sweating after inhalation of
salbutamol. In case 5 no arrhythmias were detected prior
or after the anaesthetic and no abnormalities were re-
corded on the ECG once the horse recovered, therefore
a pre-existing cardiac disease seems to be unlikely in this
horse. Investigating the clinical impact of such cardiac
impairment on a longer term is difficult; variations of
lactate serum levels after salbutamol administration
could be indicative of impaired peripheral perfusion.
The arterial lactate measured after salbutamol adminis-
tration was not increased in our cases, however all the
horses underwent supportive therapy which could have
prevented the reduction of peripheral perfusion.
Cardiovascular impairment following inhalation of sal-
butamol is probably owing to systemic uptake.
In our cases, two anesthetists (DC and CA) used the
same technique to spray salbutamol into the trachea as
previously described. This technique has been described
by Robertson and Bailey [1] in clinical horses lying in
dorsal recumbency and utilized by Patschova et al. [11]
in experimental horses.
In our cases, the total number of nebulizations to be
administered was calculated on the base of measured
weight. Therefore is improbable that an absolute over-
dosage due to any procedural change could be the cause
of the observed adverse effects. However, different filling
of the canister, different humidity degree of the inner
part of the inspiratory limb and endotracheal tube and
slightly different delivered flow of the carrier gases can-
not be ruled out as factors influencing the actual dose of
drug delivered. Whether these potential differences in
the actual dose could have influenced the percentage of
systemic absorption is difficult to evaluate. More import-
antly, we did not deliver salbutamol through the MDI
adapter (PriMed Co, Largo, Florida, USA) that the previ-
ous authors [1,8] utilized. This adapter is specifically de-
signed to allow salbutamol entering the midstream of
gas flow and carrying it far down the bronchial tree
allowing its binding to the target sites; thus, in our case,
salbutamol could have precipitated earlier, leading to
partial absorption into the systemic blood stream from
the trachea. If so, a better standardization of the delivery
technique has to be taken into higher consideration and
alternative administration techniques [12] only con-
sciously advised.
Independently of the adapter, the hypothesis of a clin-
ical relevant systemic uptake of the drug was already for-
mulated by Robertson and Bailey, as they noticed an
excessive sweating in some horses, but not accompanied
by an increase in heart rate. Inhaled β2 adrenoreceptor
agonists, to which salbutamol belongs, are the most ef-
fective known bronchodilators. It has been demonstratedthat inhaled salbutamol induces acute cardiac electro-
physiologic effects in humans, especially tachycardia and
shortened node recovery time [13]. In human medicine
there is a body of evidence that β2 receptors are not only
represented into the tracheal and bronchial musculature,
but also in the atrium and ventricular myocardium and
play a significant role in physiologic and pathologic con-
ditions [14,15]. It is well known that the equine tracheal
musculature expresses predominantly β2 receptors [16];
however contrasting results are reported concerning
their concentration in the heart. Indeed, Törneke [17]
found a small proportion of β2 adrenoreceptors in the
normal equine ventricular myocardium, while Horn et al.
[18] could not demonstrate the presence of β2 adrenore-
ceptors in normal equine myocardium, and concluded
that their density increases only during heart failure. Ac-
cording to the same authors, this discrepancy between
studies could be attributed to differences among individ-
ual horses or between sites of ventricular muscle sampled.
It is also difficult to find evidence whether the prevalent
selectivity towards β2 receptors reported for salbutamol is
relevant “in vivo”. It can be hypothesized that in some
horses salbutamol could have acted as β1 agonist as well.
Therefore, the systemically absorbed salbutamol could
have caused the chronotropic effects via β1 adrenorecep-
tor activity, which are anyhow the prevalent population in
the equine heart. Alternatively, one could speculate that
horses with greater population of β2 receptors could be
more sensitive to the action of salbutamol than horses
with a smaller population.
Differently from what could be expected, the blood
pressure trend recorded concomitantly to the rhythm
modification in our 5 cases was inconsistent. Although
the specific mechanisms that control vascular tone are
not completely understood, it has been shown in rats
that increasing density of β2 receptors in the vascular
walls enhances vasorelaxation [19]. Different anaesthetic
protocols were used in the described cases. However, in
all cases, romifidine was administered as premedication
and in case 3 and 5 additionally as CRI, salbutamol be-
ing administered relatively early after the beginning of
inhalation anesthesia. Romifidine infused at the dose of
40 μg kg−1 h−1 has been reported not having influence
on the blood pressure in isoflurane anaesthetized horses
premedicated with romifidine at a standard dose of
80 μg kg−1 [20]. However, it cannot be excluded that the
hypotension observed in the case 1 and 4 was brought
about by the activation of the vascular β2 receptors,
which overcame the increased vascular resistance medi-
ated by the action of romifidine administered in pre-
medication on the α1 receptors. A decrease in stroke
volume owing to an excessive reduction of diastolic time
should also be taken into account, especially in case 4,
in which the tachycardia was major. In case 5, lidocaine
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pressure and normal cardiac rhythm: abnormal ventricu-
lar contraction or massive vascular relaxation can both
be claimed as responsible of the symptoms. Whether it
was the normalized cardiac contractility or the improved
vascular tone, the main contributor to the clinical ameli-
oration cannot be differentiated.
In two cases (case 3 and case 5) the patients received
salbutamol while they were breathing spontaneously.
The decision to administer inhalational salbutamol as a
corrective measure of inadequate PaO2 instead of start-
ing IPPV was based on the values of PaCO2 measured in
the blood. In the cases of normocapnia or slight hyper-
capnia (PaCO2 up to 55 mmHg) the preference of the
authors was to allow the patients to breath spontan-
eously. Although the difference between the amount of
drug delivered through a negative and a positive pres-
sure driven inspiratory phase has never been tested, it is
unlikely that a lower tidal volume can be correlated with
a higher percentage of inspired salbutamol after a non-
preset inspiratory act. In case 3, the spirometry was not
included in the monitoring, but in case 5 a tidal volume
of 5.6 L was recorded from the Pitot tube and this vol-
ume is lower than the volume one would have set in a
regimen of mechanical ventilation. Therefore it is un-
likely that the spontaneous breathing could have been
the cause of increased inspired salbutamol. However it is
worth mentioning that the inhalation of salbutamol has
been previously described in horses under controlled
ventilation, which implies a different respiratory me-
chanics from spontaneous breathing. When considering
either the efficacy of the technique or the collateral ef-
fects observed, this variable has also to be taken into
account.
It is also difficult to define which cut-off of PaO2
should be chosen to plan a salbutamol treatment. In fact,
due to the great affinity of equine hemoglobin for oxy-
gen, absolute hypoxemia is arbitrarily defined as a PaO2
lower than 60 mmHg [12,21]. However, suboptimal
PaO2 reflecting an inadequacy of ventilation can be
identified in horses during general anesthesia and still
represents a therapeutic challenge. PaO2 might even not
improve, as observed in case 3, if inhalation of salbuta-
mol is provided at higher PaO2 without addressing other
potential causes of hypoxia. Furthermore, if the improve-
ment of the PaO2 is not followed by an increase in the
oxygen delivery, due to harmful cardiovascular alter-
ations, the therapeutic intervention may be useless or
even harmful. Since the consequences of relative and ab-
solute hypoxia in equine anesthesia are still not com-
pletely understood, and seem not be major [22], in the
light of the potential complications observed, it is prob-
ably worth limiting the use of salbutamol to the cases of
true hypoxia non-responsive to mechanical ventilation.In conclusion, taking into account that significant car-
diovascular effects of inhaled salbutamol can occur in
horses as reported in humans, the use of inhaled salbu-
tamol should not be considered completely harmless
and its use has to be pondered. Other therapeutic op-
tions to improve oxygenation should be considered in
spontaneous breathing horses. If the case, supportive
therapy is required and crystalloids, dobutamine, phenyl-
ephrine and lidocaine can be administered for the treat-
ments of salbutamol side effects. No further adverse
consequences were either recorded until the end of gen-
eral anesthesia or during the recovery phase.Consent
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